<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926158</url>
  </required_header>
  <id_info>
    <org_study_id>ISS 20109714</org_study_id>
    <secondary_id>2011-000628-14</secondary_id>
    <nct_id>NCT01926158</nct_id>
  </id_info>
  <brief_title>Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women</brief_title>
  <acronym>ProliaHip</acronym>
  <official_title>Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women: a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial will evaluate the efficacy of an antiresorptive osteoporosis&#xD;
      drug (denosumab) in prevention of periprosthetic bone loss and in promotion of implant&#xD;
      osseointegration (bone bonding) in postmenopausal women after total hip replacement. The&#xD;
      investigators assume that denosumab prevents periprosthetic bone loss and enhances bone&#xD;
      bonding of the hip stem in postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind and placebo-controlled trial to evaluate the efficacy of&#xD;
      denosumab on the biologic incorporation of cementless hip prosthesis. The study population&#xD;
      consists of sixty-eight postmenopausal female patients, who are scheduled to have cementless&#xD;
      total hip replacement (THA) for primary hip osteoarthritis. The patients will be randomly&#xD;
      assigned to receive a subcutaneous injection of denosumab 60 mg or placebo four weeks before&#xD;
      surgery and 22 weeks after surgery. The primary hypothesis is that denosumab is effective in&#xD;
      preventing periprosthetic bone loss in the proximal femur as measured by DXA. The secondary&#xD;
      hypothesis is that denosumab is effective in enhancement of bone bonding (osseointegration)&#xD;
      of cementless femoral stems, as measured by model-based radiostereometric analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">February 4, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Periprosthetic bone mineral density (BMD)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Periprosthetic BMD of the proximal femur will be measured according to seven Gruen zones and compared with the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiostereometric analysis (RSA) of prosthesis stem migration</measure>
    <time_frame>48 weeks</time_frame>
    <description>The translatory and rotatory migration of the femoral stem will be measured by means of model-based RSA and compared with the position at the baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional recovery</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate if the enhanced incorporation of hip prostheses in denosumab treated patients compared to placebo leads to faster functional recovery as measured by main parameters of gait analysis, pedometer evaluation of walking activity and patient reported outcome measures</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Hip Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of denosumab 60 mg 4 weeks before surgery and 22 weeks after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection of placebo 4 weeks before surgery and 22 weeks after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumb</intervention_name>
    <description>Prefilled syringe of 1 mL denosumab solution</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Brand name: Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for denosumab)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Prefilled syringe of 1 mL placebo solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women, age: ≥ 60 years to ≤ 85 years at randomization&#xD;
&#xD;
          -  Degenerative primary hip osteoarthritis as the indication of hip replacement&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of severe osteoporosis (T-score less than -4.0 and a previous fracture)&#xD;
&#xD;
          -  Presence of Dorr C-type geometric change of the proximal femur&#xD;
&#xD;
          -  Evidence of secondary osteoporosis&#xD;
&#xD;
          -  Clinical or laboratory evidence of hepatic disease&#xD;
&#xD;
          -  Laboratory evidence of hypocalcaemia&#xD;
&#xD;
          -  Vitamin D deficiency (serum 25-OH(D) &lt; 12 ng/mL)&#xD;
&#xD;
          -  Disorders of parathyroid function&#xD;
&#xD;
          -  Uncontrolled hyperthyroidism or hypothyroidism&#xD;
&#xD;
          -  History of malignancy, radiotherapy or chemotherapy for malignancy (except basal cell&#xD;
             carcinoma of the skin) within the last 5 years&#xD;
&#xD;
          -  History of osteonecrosis of the jaw&#xD;
&#xD;
          -  History of recent tooth extraction or other dental surgery and/or invasive dental work&#xD;
             planned in the next 2 years&#xD;
&#xD;
          -  Severe asthma or chronic obstructive pulmonary disease&#xD;
&#xD;
          -  History of solid organ or bone marrow transplant&#xD;
&#xD;
          -  Use within 12 months of drugs that affect bone metabolism such as ant-osteoporotic&#xD;
             agents (including SERMS), estrogens, testosterone, and anti-epileptics:&#xD;
&#xD;
               -  Cumulative dose of 500 mg prednisone or equivalent within the last 6 months&#xD;
&#xD;
               -  Ever use of oral or iv bisphosphonates&#xD;
&#xD;
               -  Ever use of strontium ranelate or fluoride&#xD;
&#xD;
          -  Use of the following medications:&#xD;
&#xD;
               -  chronic systemic ketoconazole&#xD;
&#xD;
               -  androgens&#xD;
&#xD;
               -  cinacalcet&#xD;
&#xD;
               -  aluminum&#xD;
&#xD;
               -  lithium&#xD;
&#xD;
               -  protease inhibitors&#xD;
&#xD;
               -  gonadotropin-releasing hormone agonists&#xD;
&#xD;
          -  Rheumatoid arthritis or any other inflammatory arthritis&#xD;
&#xD;
          -  History of skeletal disorder, such as Paget's disease or osteomalacia&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  General&#xD;
&#xD;
               -  Mental, neurological or other conditions that may affect the ability to perform&#xD;
                  functional or clinical assessments required by the protocol&#xD;
&#xD;
               -  Subjects with known sensitivity or intolerance to any of the products to be&#xD;
                  administered (calcium and D-vitamin supplements, denosumab)&#xD;
&#xD;
               -  Subject will not be available for protocol-required study visits, to the best of&#xD;
                  the subject's and investigator's knowledge&#xD;
&#xD;
               -  Any other condition that, in the judgement of the investigator, may compromise&#xD;
                  the ability of the subject to give written informed consent and/or to comply with&#xD;
                  all required study procedures&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannu T Aro, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Aro HT, Alm JJ, Moritz N, Mäkinen TJ, Lankinen P. Low BMD affects initial stability and delays stem osseointegration in cementless total hip arthroplasty in women: a 2-year RSA study of 39 patients. Acta Orthop. 2012 Apr;83(2):107-14. doi: 10.3109/17453674.2012.678798. Epub 2012 Apr 11.</citation>
    <PMID>22489886</PMID>
  </reference>
  <reference>
    <citation>Moritz N, Alm JJ, Lankinen P, Mäkinen TJ, Mattila K, Aro HT. Quality of intertrochanteric cancellous bone as predictor of femoral stem RSA migration in cementless total hip arthroplasty. J Biomech. 2011 Jan 11;44(2):221-7. doi: 10.1016/j.jbiomech.2010.10.012. Epub 2010 Nov 11.</citation>
    <PMID>21074160</PMID>
  </reference>
  <reference>
    <citation>Alm JJ, Mäkinen TJ, Lankinen P, Moritz N, Vahlberg T, Aro HT. Female patients with low systemic BMD are prone to bone loss in Gruen zone 7 after cementless total hip arthroplasty. Acta Orthop. 2009 Oct;80(5):531-7. doi: 10.3109/17453670903316801.</citation>
    <PMID>19916684</PMID>
  </reference>
  <reference>
    <citation>Mäkinen TJ, Alm JJ, Laine H, Svedström E, Aro HT. The incidence of osteopenia and osteoporosis in women with hip osteoarthritis scheduled for cementless total joint replacement. Bone. 2007 Apr;40(4):1041-7. Epub 2007 Jan 17.</citation>
    <PMID>17239668</PMID>
  </reference>
  <reference>
    <citation>Mäkinen TJ, Koort JK, Mattila KT, Aro HT. Precision measurements of the RSA method using a phantom model of hip prosthesis. J Biomech. 2004 Apr;37(4):487-93.</citation>
    <PMID>14996560</PMID>
  </reference>
  <results_reference>
    <citation>Nazari-Farsani S, Finnilä S, Moritz N, Mattila K, Alm JJ, Aro HT. Is Model-based Radiostereometric Analysis Suitable for Clinical Trials of a Cementless Tapered Wedge Femoral Stem? Clin Orthop Relat Res. 2016 Oct;474(10):2246-53. doi: 10.1007/s11999-016-4930-0. Epub 2016 Jun 22.</citation>
    <PMID>27334320</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Denosumab</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Hip replacement</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Radiostereometric analysis (RSA)</keyword>
  <keyword>Dual energy X-ray absorptiometry (DXA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 3, 2018</submitted>
    <returned>October 29, 2018</returned>
    <submitted>March 12, 2021</submitted>
    <returned>April 6, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

